HIV persists because a reservoir of latently infected CD4 T cells do not express viral proteins and are indistinguishable from uninfected cells. One approach to HIV cure suggests that reactivating HIV
Background : The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48
Data from Diagnoses Form [CRF 2] Study Description A laboratory-based sub-study of ATN 061 and ATN 071 that examined the effect of early treatment (HAART at CD4+ T cells > 350 cells/mm3) followed by t
